Monday, December 10, 2012

Targeted failure of the week. Post No 32. Eribulin

Women with advanced breast cancer who were given Halaven after at least two prior chemotherapy regimens lived a median 15.9 months compared with 14.5 months for those given the Roche treatment, according to research presented today at the San Antonio Breast Cancer Symposium. The results weren’t statistically significant.
From my perspective eribulin looks nice:
Well, there is hope in the company that eribulin will be successful in earlier stages of cancer treatment. Let’s wish them good luck!

No comments:

Post a Comment